PTGS2 and Familial prostate cancer: In this context, selective COX-2 inhibitors, such as coxibs, may represent a better choice to control cancer-related pain, as they have been significantly associated with reduced mortality and fewer emergency department visits across various cancer types, including breast, colorectal, melanoma, pancreatic, liver, biliary tract, lymphohematopoietic, lung, and prostate cancers.